With focus in the COVID-19 pandemic shifting to treatments and managing severe forms of the disease, it’s important to understand how health economists capture these dynamics to estimate the value of antiviral treatments. Precision’s Jacquelyn W. Chou, Marissa Baker-Wagner, Marlon Graf, Zachary Heim, and T. Joseph Mattingly II provide recommendations for aligning the actual practice of value assessment of antivirals with best practice guidelines
